title: A Direct Oral Anticoagulant as a Cost Effective Alternative to Warfarin for Treatment of Provoked Venous Thrombosis.
abstract: In Ireland, Warfarin is the primary anticoagulant prescribed in the secondary prevention of provoked DVT. We completed a comprehensive cost analysis of a trial group of 24 patients treated with Rivaroxaban (between November 2013 and December 2014), versus a control group treated with Warfarin (between January 2008 and November 2013). The groups were matched for gender (3/7 M/F ratio), DVT type (5 proximal, 19 distal DVTs), provoking factor (20 traumatic, 4 atraumatc), and age. We calculated the cost for each group based on drug administration and clinic costs (labour, sample analysis, and additional costs). Warfarin patients attended clinic 14.58 times; Rivaroxaban patients attended 2.92 times. Overall, the cost per patient on Rivaroxaban is €273.30 versus €260.68 with warfarin. This excludes patient costs which would further increase cost of Warfarin therapy.
authors.affiliation: Department of Haematology, University Hospital Limerick, Dooradoyle, Limerick.
authors.forename: W
authors.initials: W
authors.lastname: Courtney
authors.affiliation: Department of Haematology, University Hospital Limerick, Dooradoyle, Limerick.
authors.forename: E
authors.initials: E
authors.lastname: Groarke
authors.affiliation: Department of Haematology, University Hospital Limerick, Dooradoyle, Limerick.
authors.forename: J
authors.initials: J
authors.lastname: Conway
authors.affiliation: Department of Haematology, University Hospital Limerick, Dooradoyle, Limerick.
authors.forename: E
authors.initials: E
authors.lastname: Conway
authors.affiliation: Department of Haematology, University Hospital Limerick, Dooradoyle, Limerick.
authors.forename: D
authors.initials: D
authors.lastname: Bourke
authors.affiliation: Department of Maths and Statistics, University of Limerick, Limerick.
authors.forename: J
authors.initials: J
authors.lastname: Saunders
authors.affiliation: 3Department of Medicine, University Hospital Limerick, Dooradoyle, Limerick, Ireland.
authors.forename: M
authors.initials: M
authors.lastname: Watts
authors.affiliation: Department of Haematology, University Hospital Limerick, Dooradoyle, Limerick.
authors.forename: D
authors.initials: D
authors.lastname: O'Keefe
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage / Q000191:economics*; D003365:Costs and Cost Analysis; D016527:Drug Costs; D065427:Factor Xa Inhibitors / Q000008:administration & dosage / Q000191:economics*; D005260:Female; D006801:Humans; D007494:Ireland; D008297:Male; D000069552:Rivaroxaban / Q000008:administration & dosage / Q000191:economics*; D055502:Secondary Prevention / Q000191:economics; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000209:etiology; D014859:Warfarin / Q000008:administration & dosage / Q000191:economics*
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D014859:Warfarin; D000069552:Rivaroxaban